General Information of the Drug (ID: M6APDG04232)
Name
ZN-c3
Status
Phase 2
TTD Drug ID
DRQN21
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Wee1-like protein kinase (WEE1)
Protein virilizer homolog (VIRMA)
In total 1 mechanisms lead to this potential drug response
Response Summary Wee1-like protein kinase (WEE1) is a therapeutic target for ZN-c3. The Protein virilizer homolog (VIRMA) has potential in affecting the response of ZN-c3 through regulating the expression of Wee1-like protein kinase (WEE1). [1], [2]
References
Ref 1 KIAA1429 is a potential prognostic marker in colorectal cancer by promoting the proliferation via downregulating WEE1 expression in an m6A-independent manner. Oncogene. 2022 Jan;41(5):692-703. doi: 10.1038/s41388-021-02066-z. Epub 2021 Nov 24.
Ref 2 National Cancer Institute Drug Dictionary (drug id 770319).